Oxford Biomedica Dirección

Dirección controles de criterios 1/4

El CEO de Oxford Biomedica's es Frank Mathias, nombrado en Mar 2023, tiene una permanencia de 1.08 años. posee directamente un 0.02% de las acciones de la empresa, con un valor de £43.70K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 3.8 años, respectivamente.

Información clave

Frank Mathias

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.2yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oct 19

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Aug 23

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 15

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Oct 06

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

May 02

Investors Who Bought Oxford Biomedica (LON:OXB) Shares Five Years Ago Are Now Up 202%

Dec 24

The Independent Non-Executive Director of Oxford Biomedica plc (LON:OXB), Andrew John Heath, Just Sold 79% Of Their Holding

Dec 02

Oxford Biomedica (LON:OXB) Is In A Good Position To Deliver On Growth Plans

Dec 01

CEO

Frank Mathias (61 yo)

1.2yrs

Permanencia

Dr. Frank Mathias is Chief Executive Officer and Director of Oxford Biomedica plc from March 27, 2023. Dr. Mathias was the Chief Executive Officer of Rentschler Biopharma SE from April 2016 until March 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Paynter	CFO & Director	6.8yrs	UK£888.00k	0.019% £ 61.3k
Frank Mathias	CEO & Director	1.2yrs	sin datos	0.020% £ 65.6k
Thierry Cournez	COO & Oxford Site Head	less than a year	sin datos	sin datos
James Miskin	Chief Quality & Technical Officer	no data	sin datos	0.14% £ 466.0k
Matthew Treagus	Chief Information Officer	2.8yrs	sin datos	0.0097% £ 31.9k
Sophia Bolhassan	Head of Investor Relations	no data	sin datos	sin datos
Natalie Walter	General Counsel & Company Secretary	5yrs	sin datos	sin datos
Lisa James	Chief People Officer	2.1yrs	sin datos	sin datos
Kyriacos Mitrophanous	Chief Innovation Officer	less than a year	sin datos	sin datos
Kati Hudson	Head of Intellectual Property and Contracts	no data	sin datos	sin datos
Sebastien Ribault	Chief Commercial Officer	1.5yrs	sin datos	sin datos
Mark Caswell	Site Head of US Operations	less than a year	sin datos	sin datos

1.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OXB no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stuart Paynter	CFO & Director	6.8yrs	UK£888.00k	0.019% £ 61.3k
Frank Mathias	CEO & Director	1.2yrs	sin datos	0.020% £ 65.6k
Michael Hayden	Non-Independent Non-Executive Director	2.8yrs	UK£130.00k	0.040% £ 131.1k
Frederic Doliveux	Non-Executive Chair	3.9yrs	UK£1.16m	0.37% £ 1.2m
William Langston	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Stern	Member of Scientific Advisory Board	no data	sin datos	sin datos
Krystof Bankiewicz	Member of Scientific Advisory Board	no data	sin datos	sin datos
Heather Preston	Independent Non-Executive Director	6.2yrs	UK£140.00k	0.018% £ 60.0k
Dame Davies	Senior Independent Director	3.2yrs	UK£65.00k	0.0010% £ 3.3k
Catherine Moukheibir	Independent Non-Executive Director	2.4yrs	UK£140.00k	0.026% £ 84.5k
Stuart Henderson	Independent Vice Chair	7.9yrs	UK£85.00k	0.011% £ 35.6k
Robert Ghenchev	Non-Executive Director	4.9yrs	sin datos	sin datos

3.9yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de OXB se considera experimentada (3.8 años de antigüedad promedio).

Oxford Biomedica Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Oxford Biomedica plc Announces Board Changes

Non-Executive Chair recently bought UK£99k worth of stock

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

High number of new directors

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Recent updates

Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc to Report Fiscal Year 2023 Results on Apr 29, 2024

New minor risk - Shareholder dilution

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc Provides Business Update

Consensus EPS estimates fall by 12%

Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for €15 million.

Price target decreased by 9.5% to UK£6.79

New minor risk - Share price stability

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Consensus revenue estimates fall by 27%

Non-Executive Chair recently bought UK£99k worth of stock

Oxford Biomedica Talks to Buy ABL Europe

Oxford Biomedica Talks to Buy ABL Europe

First half 2023 earnings: EPS and revenues miss analyst expectations

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Price target decreased by 11% to UK£8.21

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Oxford Biomedica plc to Report First Half, 2023 Results on Sep 20, 2023

Price target decreased by 8.2% to UK£10.00

Oxford Biomedica plc Launches TetraVectaTM - the Next Generation Lendediviral Vector System

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Price target increased by 40% to UK£11.83

Price target decreased by 25% to UK£8.43

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 25% to UK£8.43

High number of new directors

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Consensus forecasts updated

Oxford Biomedica Appoints Frank Mathias as Board Director

High number of new directors

Kadans Science Partner B.V. agreed to acquire Windrush Court facility from Oxford Biomedica plc (LSE:OXB) for £60 million.

Price target decreased to UK£11.19

Consensus forecasts updated

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Consensus forecasts updated

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Oxford Biomedica plc Provides Earnings Guidance for the Second Half of 2022

Oxford Biomedica plc to Report First Half, 2022 Results on Sep 15, 2022

Oxford Biomedica plc(LSE:OXB) dropped from FTSE 350 Index (GBP)

Investor sentiment deteriorated over the past week

Oxford Biomedica Notes Announcement That FDA Has Lifted Clinical Hold on Homology Medicines' Phenix Trial

John Dawson Has Steps Down from the Oxford Biomedica Plc's Board of Directors

Consensus forecasts updated

Price target decreased to UK£14.99

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

High number of new directors

Interim CEO & Chairman recently bought UK£343k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 136%

Oxford Biomedica plc Provides Revenue Guidance for the Year 2022

Oxford Biomedica plc Announces the Appointment of Namrata P Patel as Independent Non-Executive Director

Oxford Biomedica plc to Report Fiscal Year 2021 Results on Apr 20, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc, Annual General Meeting, Mar 08, 2022

Investor sentiment deteriorated over the past week

Price target increased to UK£18.42

Oxford Biomedica plc announced that it expects to receive £50.000001 million in funding

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.087 loss in 1H 2020)

Price target increased to UK£17.00

Price target increased to UK£14.82

We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Price target increased to UK£13.52

Non-Executive Director Andrew John Heath has left the company